Why is Plus Therapeutics (PSTV) Stock Rising Today?
Plus Therapeutics (Nasdaq: PSTV) might see its stock rise further thanks to some promising new clinical data about its lead treatment, REYOBIQ™ (rhenium Re186 obisbemeda). This info was shared ahead of a presentation at the upcoming Nuclear Medicine and Neuro-oncology Conference in Vienna this May, and it really highlights the company’s unique approach to tackling central nervous system (CNS) cancers, especially leptomeningeal metastases—an extremely tough type of cancer to treat.
In the Phase 1 ReSPECT-LM dose escalation trial, REYOBIQ showed that increasing the radiation dose to the brain and spinal cord worked, with one group receiving an average dose of 253Gy, which is considered potentially effective. Out of the 16 patients assessed, 31% had partial responses, and 44% showed stable disease, giving a clinical benefit rate of 75%. Doctors had similar assessments, reporting an 86% clinical benefit rate.
Importantly, there were no serious side effects reported in the first four patient groups, and only two instances of severe thrombocytopenia (low platelet count) occurred in the higher dose groups. This suggests a favorable safety profile so far.
These results are significant for long term shareholders. With limited treatment options for leptomeningeal metastases and a growing demand for targeted radiotherapies, Plus Therapeutics is positioned in a valuable niche. Their technology platform for targeted radiotherapy could lead to broader revenue opportunities.
As the biotech sector rebounds and investors shift focus toward companies with solid clinical data, Plus Therapeutics’ strong results and upcoming conference presentations could keep the momentum going for their stock. At the time of writing PSTV stock is gaining 39% in premarket session.
